DelveInsight’s “Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast 2032″ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Renal Cell Carcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Renal Cell Carcinoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Renal Cell Carcinoma: An Overview
In Renal Cell Carcinoma (RCC), cancerous (malignant) cells develop in the lining of the kidney tubules and grow into a mass called a tumor. Like many other cancers, the growth begins small and grows larger over time, It typically grows as a single mass. However, there are cases where a kidney may contain more than one tumor, or tumors are found in both kidneys simultaneously.
Over a dozen subtypes of renal cell carcinoma are identified by examining the tumor under a microscope. The most common types are Clear Cell, Papillary, Chromophobe, Clear cell papillary, Collecting Duct, and Medullary.
Renal Cell Carcinoma Market Key Facts
According to the Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts: Renal Cell Carcinoma, 74,000 new cases of kidney cancer were diagnosed in 2019, accounting for 4.2% of all cancer diagnoses (almost double the global average). Renal cell carcinoma (RCC) accounts for 2% of global cancer diagnoses and deaths.
The incident cases of Renal cell carcinoma in seven major markets were found to be 138,500+ in 2021.
The highest number of incident cases of the disease were observed in the United States, with 55,700+ cases, and the EU-5 countries accounted for 60,700+ cases.
In Japan, the cases of RCC were found to be 22,000+ in 2021.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Renal Cell Carcinoma market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Renal Cell Carcinoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Renal Cell Carcinoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Renal Cell Carcinoma Epidemiology, Segmented as –
Incident Cases of RCC (2019-2032)
Stage-specific Diagnosed Incident Cases of RCC (2019-2032)
Incident Cases of Kidney Cancer (2019-2032)
Gender-specific Diagnosed Incident of RCC (2019-2032)
Subtype-specific Diagnosed Incident of RCC (2019-2032)
Advanced RCC Progression from Localized to Advanced RCC (2019-2032)
Renal Cell Carcinoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Renal Cell Carcinoma market or expected to be launched during the study period. The analysis covers the Renal Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Renal Cell Carcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Renal Cell Carcinoma Market Will Evolve and Grow by 2032 @
Renal Cell Carcinoma Therapeutics Analysis
The treatment landscape of Renal Cell Carcinoma is governed by targeted therapies and immunotherapies. Most of the targeted drugs used to treat kidney cancer work by blocking angiogenesis (growth of the new blood vessels that feed cancers) or important proteins in cancer cells (called tyrosine kinases) that help them grow and survive.
Several major pharma and biotech giants are developing therapies for Renal Cell Carcinoma to improve the treatment scenario further. Currently, Betta Pharmaceuticals is leading the therapeutics market with its Renal Cell Carcinoma drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Renal cell carcinoma Therapeutics Market Include:
Akesobio, Allogene Therapeutics, Amgen, Aravivie Inc, AstraZeneca, Aveao pharmaceuticals, Bayer Healthcare, Betta Pharmaceuticals, Bristol-Myers Squibb, Cemiplimab, Chia Tai Tianqing Pharmaceutical, ColImmune, Corvus Pharmaceuticals, CRISPR Therapeutics, GlaxoSmithKline, Hoffman La Roche, Incyte Corporation, Infinity Pharmaceuticals, Ipsen, Merck Sharp & Dohme Corp., Novartis, Pfizer, Regeneron Pharmaceuticals, X4 pharmaceuticals, and many others.
Renal Cell Carcinoma Emerging and Marketed Drugs Covered in the Report Include:
AK104 Plus Axitinib: Akesobio
ALLO-316: Allogene Therapeutics
Ciforadenant: Corvus Pharmaceuticals
CM082: Betta Pharmaceuticals
CTX130: CRISPR Therapeutics
IPI-549: Infinity Pharmaceuticals
TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Renal Cell Carcinoma Competitive Intelligence Analysis
4. Renal Cell Carcinoma Market Overview at a Glance
5. Renal Cell Carcinoma Disease Background and Overview
6. Renal Cell Carcinoma Patient Journey
7. Renal Cell Carcinoma Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Renal Cell Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Renal Cell Carcinoma Unmet Needs
10. Key Endpoints of Renal Cell Carcinoma Treatment
11. Renal Cell Carcinoma Marketed Products
12. Renal Cell Carcinoma Emerging Drugs and Latest Therapeutic Advances
13. Renal Cell Carcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Renal Cell Carcinoma Market Outlook (In US, EU5, and Japan)
16. Renal Cell Carcinoma Access and Reimbursement Overview
17. KOL Views on the Renal Cell Carcinoma Market
18. Renal Cell Carcinoma Market Drivers
19. Renal Cell Carcinoma Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Solutions
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States